• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Belviq (Lorcaserin): A 5-HT2C receptor agonist indicated to treat certain overweight or obese adults

News
Article

New molecular entity: FDA approved Lorcaserin (Belviq, Arena Pharmaceuticals GMBH), as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index deemed obese and the presence of at least 1 weight-related comorbid condition.

Obesity increases patients' risk of heart disease, stroke, type 2 diabetes, and certain types of cancer, and costs the healthcare system about $147 billion per year. On June 27, 2012, FDA approved lorcaserin as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of at least 1 weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes).

Efficacy. Lorcaserin is believed to decrease food consumption and promote satiety by selectively activating 5-HT2C receptors located in the hypothalamus. Lorcaserin 10 mg twice daily was evaluated in 3 randomized, double-blind, placebo-controlled trials with durations of at least 52 weeks (2 in adults without type 2 diabetes and 1 study in adults with type 2 diabetes). Statistically significantly greater weight loss was achieved with lorcaserin in both non-diabetics compared to placebo at week 52 (placebo-adjusted weight loss with lorcaserin was 3.3 kg, 95% CI, -3.6, -3.0) and in type 2 diabetics (placebo-adjusted weight loss with lorcaserin was 3.1 kg, 95% CI, -3.9, -2.2). Moreover, about 47% of patients without type 2 diabetes lost ≥5% of their body weight compared with 23% of patients treated with placebo. In patients with type 2 diabetes, 38% of patients treated with lorcaserin lost ≥5% of their body weight versus 16% receiving placebo.

Safety. In clinical trials of lorcaserin lasting at least 1 year, the most common adverse reactions occurring in >5% of non-diabetic patients were headache, dizziness, fatigue, nausea, dry mouth, and constipation. In diabetic patients, the most common adverse reactions were hypoglycemia, headache, back pain, cough, and fatigue. Other safety concerns included: serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reactions, hypoglycemia (due to weight loss in type 2 diabetics), valvular heart disease, cognitive impairment, psychiatric disorders (ie, euphoria, hallucination, and dissociation), heart rate decreases (of ~1.2 to 2.0 beats per minute), decreases in red and white blood cell counts, and priapism. The drug's manufacturer will be required to conduct 6 postmarketing studies, including a long-term cardiovascular outcomes trial to assess the effect of lorcaserin on the risk for major adverse cardiac events such as heart attack and stroke.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.